Compare CCNE & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCNE | DSGN |
|---|---|---|
| Founded | 1865 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 853.8M |
| IPO Year | 1995 | 2021 |
| Metric | CCNE | DSGN |
|---|---|---|
| Price | $33.38 | $9.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $38.00 | $21.71 |
| AVG Volume (30 Days) | 116.6K | ★ 638.8K |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | ★ 4.18 | N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.41 | N/A |
| Revenue Next Year | $5.38 | N/A |
| P/E Ratio | $18.87 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.90 | $5.28 |
| 52 Week High | $36.17 | $17.25 |
| Indicator | CCNE | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.24 | 23.20 |
| Support Level | $32.84 | N/A |
| Resistance Level | $35.06 | $10.17 |
| Average True Range (ATR) | 0.62 | 0.65 |
| MACD | -0.01 | -0.21 |
| Stochastic Oscillator | 36.51 | 8.22 |
CNB Financial Corp is a Pennsylvania-chartered bank. The bank is a full-service bank engaging in a full range of banking activities and services for individual, business, governmental and institutional customers. These activities and services principally include checking, savings, and time deposit accounts; real estate, commercial, industrial, residential and consumer loans; and a variety of other specialized financial services. Its Private Client Solutions division offers a full range of client services, including private banking and wealth and asset management. The banking segment derives its revenue through the operations as a full-service bank services, including trust and wealth management services, for individual, business, governmental, and institutional customers.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.